Edgewise Therapeutics, Inc. (EWTX)

Edgewise Therapeutics' stock (EWTX) has experienced a significant decline of 55.84% over the past six months and approximately 56.60% over the last year. RBC Capital reaffirmed an 'Outperform' rating for Edgewise Therapeutics, maintaining a price target of $48.00 USD. Edgewise Therapeutics reported its Second Quarter 2025 financial results and recent business highlights and inducement grants. Pomerantz Law Firm issued an "INVESTOR ALERT," investigating claims on behalf of investors of Edgewise Therapeutics, Inc. Edgewise Therapeutics reported inducement grants and announced plans to present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society. The stock price experienced fluctuations, including falling below its 50-day and 15-day moving averages on October 22, 2025, and exceeding its daily average trading volume on October 20, 2025.

There is limited data available to indicate significant demand seasonality for Edgewise Therapeutics, Inc.'s products and services, suggesting that strong seasonality is not a prominent or well-documented factor for EWTX.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines for severe, rare muscle disorders and serious cardiac conditions. The company utilizes a proprietary drug discovery platform to identify small molecule precision medicines that regulate key proteins in muscle tissue. Their major product candidates include Sevasemten (EDG-5506), an orally administered skeletal myosin inhibitor in late-stage clinical trials for dystrophinopathies, and EDG-7500, a novel cardiac sarcomere modulator in Phase II clinical development for hypertrophic cardiomyopathy.

Edgewise Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, and Boulder, Colorado, United States. Clinical trials for Sevasemten (EDG-5506) are being conducted in the U.S., Israel, certain countries in Europe, and Australasia.

Edgewise Therapeutics' reputation has been shaped by its ongoing clinical advancements and some corporate events. The company has actively presented its research on Sevasemten for muscular dystrophies at scientific congresses, which generally contributes positively to its scientific standing. However, an "INVESTOR ALERT" from Pomerantz Law Firm in August 2025, investigating claims on behalf of investors, could have negatively impacted the company's brand reputation among the investment community.

Institutional shareholders hold approximately 72.04% of the outstanding shares of Edgewise Therapeutics, Inc., with some sources indicating institutional ownership as high as 112.71% or around 19.94%. Major institutional owners include Orbimed Advisors LLC, Ra Capital Management LP, Baker Bros Advisors LP, BlackRock, Inc., Paradigm Biocapital Advisors LP, Janus Henderson Group Plc, Novo Holdings A/S, Braidwell Lp, Vanguard Group Inc, and Perceptive Advisors Llc. Holdings A. Novo is identified as the largest individual shareholder, owning 6.07 million shares, representing 5.76% of the company. Insiders own approximately 0.56% to 14.85% of the stock.